Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

Eur Psychiatry. 2009 Sep;24(6):412-24. doi: 10.1016/j.eurpsy.2009.01.005. Epub 2009 Aug 13.

Abstract

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

MeSH terms

  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / epidemiology*
  • Bipolar Disorder / mortality
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control
  • Cause of Death
  • Comorbidity
  • Cross-Sectional Studies
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / epidemiology*
  • Depressive Disorder, Major / mortality
  • Diabetes Mellitus / chemically induced
  • Diabetes Mellitus / epidemiology*
  • Diabetes Mellitus / mortality
  • Diabetes Mellitus / prevention & control
  • Follow-Up Studies
  • Humans
  • Mass Screening
  • Obesity / epidemiology
  • Practice Guidelines as Topic
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / epidemiology*
  • Psychotic Disorders / mortality
  • Psychotropic Drugs / adverse effects
  • Psychotropic Drugs / therapeutic use
  • Risk Factors
  • Schizophrenia / drug therapy
  • Schizophrenia / epidemiology*
  • Schizophrenia / mortality
  • Societies, Medical*

Substances

  • Psychotropic Drugs